Norvir (Ritonavir)

• Norvir is a protease inhibitor used within antiretroviral therapy to target HIV‑1 replication and to enhance the effectiveness of other protease inhibitors.
• HIV‑1 infection: reduces viral load when combined with other antiretroviral agents.
• Pharmacokinetic booster: increases plasma concentrations of co‑administered protease inhibitors, allowing lower dosing.
• Combination antiretroviral regimens: contributes to sustained viral suppression as part of multi‑drug therapy.

• Ritonavir inhibits the HIV‑1 protease enzyme, preventing cleavage of the gag‑pol polyprotein required for maturation of infectious viral particles. By binding to the active site of the protease, it halts viral replication. Additionally, ritonavir is a potent inhibitor of the cytochrome P450 3A4 isozyme, which reduces the metabolic clearance of other protease inhibitors, thereby boosting their plasma concentrations.

Ritonavir may cause a range of adverse reactions, from mild to severe. Monitoring and reporting of side effects are essential during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal discomfort.
• Diarrhea: loose stools occurring during treatment.
• Headache: transient cranial pain.
• Fatigue: reduced energy levels.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or liver injury.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• QT prolongation: cardiac rhythm disturbance that may lead to arrhythmia.
• Severe allergic reactions: rash, angioedema, or anaphylaxis.
• Lipodystrophy: abnormal fat redistribution.
• Hyperglycemia: increased blood glucose levels.

• Before initiating ritonavir, clinicians should assess patient history and monitor for specific risks.
• Liver function monitoring: check baseline enzymes and repeat periodically.
• Drug interaction review: evaluate concomitant medications for CYP3A4 substrates.
• Cardiac assessment: consider ECG in patients with known QT prolongation.
• Adherence counseling: emphasize importance of consistent dosing.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Ritonavir interacts with many drugs through CYP3A4 inhibition; careful management is required.

Major Interactions (Avoid)

• Simvastatin: risk of severe myopathy and rhabdomyolysis.
• Ergot derivatives (e.g., ergotamine): may cause ergotism.
• Midazolam: can lead to profound sedation and respiratory depression.

Moderate Interactions (Monitor Closely)

• Other protease inhibitors: dose adjustments may be needed.
• Anticoagulants (e.g., warfarin): monitor INR for bleeding risk.
• Oral contraceptives: efficacy may be reduced, consider alternative contraception.